These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11761965)

  • 1. [Super para magnetic iron oxide--Feridex].
    Ohtomo K
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():319-22. PubMed ID: 11761965
    [No Abstract]   [Full Text] [Related]  

  • 2. [Detection of liver lesions: magnetic resonance tomography using superparamagnetic iron particles (AMI-25, endorem) as a contrast medium in comparison with ultrasound diagnosis, computerized tomography and CT portography].
    Pleger B; Beyer HK; Laufer U
    Rontgenpraxis; 2001; 53(6):245-9. PubMed ID: 11402872
    [No Abstract]   [Full Text] [Related]  

  • 3. [Differential diagnosis of focal liver lesions using contrast-enhanced MRI with SHU 555 A in comparison with unenhanced MRI and multidetector spiral-CT].
    Jung G; Poll L; Cohnen M; Saleh A; Vogler H; Wettstein M; Willers R; Mödder U; Koch JA
    Rofo; 2005 Nov; 177(11):1571-7. PubMed ID: 16302139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Obsolete methods in examination of the liver with MRI].
    Schadmand-Fischer S
    Rofo; 1998 Dec; 169(6):679-80. PubMed ID: 9930229
    [No Abstract]   [Full Text] [Related]  

  • 5. SPIO-MRI in the detection of hepatocellular carcinoma.
    Araki T
    J Gastroenterol; 2000; 35(11):874-6. PubMed ID: 11085500
    [No Abstract]   [Full Text] [Related]  

  • 6. Liver imaging with ferumoxides (Feridex): fundamentals, controversies, and practical aspects.
    Clément O; Siauve N; Cuénod CA; Frija G
    Top Magn Reson Imaging; 1998 Jun; 9(3):167-82. PubMed ID: 9621405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [MR contrast agent: resovist (SH U 555A)].
    Nakajima H; Ichikawa T
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():328-32. PubMed ID: 11761967
    [No Abstract]   [Full Text] [Related]  

  • 8. European clinical experience with Endorem. A new contrast agent for liver MRI in 1000 patients.
    Chachuat A; Bonnemain B
    Radiologe; 1995 Nov; 35(11 Suppl 2):S274-6. PubMed ID: 8588035
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of superparamagnetic iron oxide-enhanced and gadobenate dimeglumine-enhanced dynamic MRI for detection of small hepatocellular carcinomas.
    Kim YK; Kim CS; Lee YH; Kwak HS; Lee JM
    AJR Am J Roentgenol; 2004 May; 182(5):1217-23. PubMed ID: 15100122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial for "IOP Injection, A Novel Superparamagnetic Iron Oxide Particle MRI Contrast Agent for the Detection of Hepatocellular Carcinoma: A Phase II Clinical Trial".
    Coll-Font J; Nguyen C
    J Magn Reson Imaging; 2023 Oct; 58(4):1189-1190. PubMed ID: 36820512
    [No Abstract]   [Full Text] [Related]  

  • 11. Resovist for imaging of hepatocellular carcinoma in the cirrhotic liver.
    Weishaupt D; Willmann JK; Lutz AM; Marincek B
    Eur Radiol; 2004 Jan; 14 Suppl 1():C5-6. PubMed ID: 15113059
    [No Abstract]   [Full Text] [Related]  

  • 12. Results of a multicenter phase II clinical trial with a susceptibility contrast medium for magnetic resonance imaging of the liver.
    Balzer T; Carter EC; Shamsi K; Niendorf HP
    Acad Radiol; 1996 Aug; 3 Suppl 2():S417-9. PubMed ID: 8796619
    [No Abstract]   [Full Text] [Related]  

  • 13. [The characterization value of feridex-enhanced MR imaging for focal hepatic lesions in reference to their histological pathology].
    Yang HF; Zhou XP; Yu JQ; Song B; Guang YS; Zhang HY; Chen X
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):548-50. PubMed ID: 16042902
    [No Abstract]   [Full Text] [Related]  

  • 14. [New super-paramagnetic iron particles for MRI. Phase II study of malignant liver tumors].
    Daldrup HE; Reimer P; Rummeny EJ; Tombach B; Berns T; Balzer T; Schimpfky C; Peters PE
    Radiologe; 1995 Aug; 35(8):486-93. PubMed ID: 7568792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with Resovist in gastroenterologic radiology and intervention.
    Vogl TJ; Schwarz W; Marquart F; Parmentier S; Götz B; Thalhammer A; Hammerstingl R
    Eur Radiol; 2004 Jan; 14 Suppl 1():C7-9. PubMed ID: 15113060
    [No Abstract]   [Full Text] [Related]  

  • 16. Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.
    Kim SH; Choi D; Kim SH; Lim JH; Lee WJ; Kim MJ; Lim HK; Lee SJ
    AJR Am J Roentgenol; 2005 Apr; 184(4):1069-76. PubMed ID: 15788575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Contrast-enhanced sonography using Levovist is decisive for staging and therapeutic schedule in hepatocellular carcinoma].
    von Herbay A; Donner A; Jung G; Vogt C; Häussinger D
    Med Klin (Munich); 2004 Feb; 99(2):89-92. PubMed ID: 14963659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of combining sequentially acquired gadobenate dimeglumine-enhanced magnetic resonance imaging and resovist-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: comparison with computed tomography hepatic arteriography and computed tomography arterioportography using 16-slice multidetector computed tomography.
    Kim YK; Kwak HS; Han YM; Kim CS
    J Comput Assist Tomogr; 2007; 31(5):702-11. PubMed ID: 17895780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Will ferumoxides-enhanced MR imaging replace CT during arterial portography in the detection of hepatic metastases? Prologue to a promising future.
    Soyer P
    Radiology; 1996 Sep; 200(3):610-1. PubMed ID: 8756902
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatocellular carcinoma: depiction of tumor parenchymal flow with intermittent harmonic power Doppler US during the early arterial phase in dual-display mode.
    Ding H; Kudo M; Onda H; Suetomi Y; Minami Y; Maekawa K
    Radiology; 2001 Aug; 220(2):349-56. PubMed ID: 11477236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.